|Mr. Joshua H. Levine||Pres, CEO & Director||739.26k||N/A||1958|
|Mr. Shigeyuki Hamamatsu||Sr. VP & CFO||420.51k||N/A||1973|
|Mr. Patrick R. Spine||Sr. VP & Chief Admin. Officer||395.87k||N/A||1971|
|Mr. Jesse Chew||Sr. VP, Gen. Counsel & Corp. Sec.||396.02k||N/A||1981|
|Ms. Suzanne Winter||Chief Commercial Officer and Sr. VP of R&D||657.6k||N/A||1963|
|Mr. Michael Hoge||Sr. VP of Global Operations||N/A||N/A||N/A|
|Ken Mobeck||VP of Fin. & Investor Relations||N/A||N/A||N/A|
|Beth Kaplan||PR Director||N/A||N/A||N/A|
|Mr. Scott Chapman||Sr. VP of Global Service||N/A||N/A||N/A|
|Mr. Jim Dennison||Sr. VP of Global Quality & Regulatory Affairs||N/A||N/A||N/A|
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body in the Americas, Europe, the Middle East, India, Japan, Africa, and rest of the Asia Pacific region. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. Its CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables the delivery of precise, high dose radiation while patients breathe normally. The company also offers the TomoTherapy System, including the Radixact System, which consists of an integrated and versatile radiation therapy system used for the treatment of a range of cancer types. It markets its products in the United States directly, as well as through sales organizations, sales agents, and group purchasing organizations; and directly, as well as through distributors and sales agents in Europe, Asia, and South America to hospitals and stand-alone treatment facilities. The company was incorporated in 1990 and is headquartered in Sunnyvale, California.
Accuray Incorporated’s ISS Governance QualityScore as of January 22, 2021 is 3. The pillar scores are Audit: 1; Board: 1; Shareholder Rights: 6; Compensation: 3.